Immunotherapy is rewriting the rules of childhood leukaemia, and a Newcastle University study shows just how thoroughly. Analysing more than 200 young patients with B-cell acute lymphoblastic leukaemia treated with blinatumomab across 24 centres in the UK and Ireland, researchers found that the classic predictors of relapse, including age, white blood cell count and pre-treatment residual disease, lost much of their reliability once the antibody therapy replaced parts of standard chemotherapy.
What mattered instead was response. The amount of leukaemia remaining after the first cycle of blinatumomab emerged as the strongest predictor of relapse, while two genetic subtypes, IKZF1plus and DUX4-rearranged disease, were associated with poorer responses and higher risk. The team, co-led by Newcastle and Great Ormond Street Hospital, combined early response data with genetics into a practical risk tool named BlinPredict, published in Blood Advances.
The implications are immediate rather than hypothetical. The findings have already prompted revisions to UK treatment guidelines, and the stratification they enable could allow some children to be spared unnecessary chemotherapy while directing intensified treatment to those genuinely at risk. For a field in which cure rates are high but treatment burden remains heavy, recalibrating risk for the immunotherapy era is a significant step.